

Old Dominion University ODU Digital Commons

Bioelectrics Publications

Frank Reidy Research Center for Bioelectrics

12-2015

Donor Platelet Plasma Components Inactivate Sensitive and Multidrug Resistant *Acinetobacter Baumannii* Isolates

Chelsea M. Edelblute
Old Dominion University


Olga N. Pakhomova
Old Dominion University, opakhomo@odu.edu

Fanying Li
Old Dominion University

Barbara Y. Hargrave
Old Dominion University, bhargrav@odu.edu

Loree C. Heller
Old Dominion University, lheller@odu.edu

Follow this and additional works at: https://digitalcommons.odu.edu/bioelectrics_pubs

 Part of the [Diseases Commons](#), [Immunology and Infectious Disease Commons](#), and the [Pathogenic Microbiology Commons](#)

Repository Citation

Edelblute, Chelsea M.; Pakhomova, Olga N.; Li, Fanying; Hargrave, Barbara Y.; and Heller, Loree C., "Donor Platelet Plasma Components Inactivate Sensitive and Multidrug Resistant *Acinetobacter Baumannii* Isolates" (2015). *Bioelectrics Publications*. 221. https://digitalcommons.odu.edu/bioelectrics_pubs/221

Original Publication Citation

Edelblute, C. M., Pakhomova, O. N., Li, F. Y., Hargrave, B. Y., & Heller, L. C. (2015). Donor platelet plasma components inactivate sensitive and multidrug resistant *Acinetobacter baumannii* isolates. *Pathogens and Disease*, 73(9), ftv095. doi:10.1093/femspd/ftv095

This Article is brought to you for free and open access by the Frank Reidy Research Center for Bioelectrics at ODU Digital Commons. It has been accepted for inclusion in Bioelectrics Publications by an authorized administrator of ODU Digital Commons. For more information, please contact digitalcommons@odu.edu.

SHORT COMMUNICATION

Donor platelet plasma components inactivate sensitive and multidrug resistant *Acinetobacter baumannii* isolates

Chelsea M. Edelblute¹, Olga N. Pakhomova¹, Fanying Li¹,
Barbara Y. Hargrave^{1,2} and Loree C. Heller^{1,2,*}

¹Frank Reidy Research Center for Bioelectrics, Old Dominion University, 4211 Monarch Way, Suite 300 Norfolk, VA 23508, USA and ²School of Medical Diagnostic & Translational Sciences College of Health Sciences Old Dominion University Norfolk, VA 23529, USA

*Corresponding author: Frank Reidy Research Center for Bioelectrics Old Dominion University 4211 Monarch Way, Suite 300 Norfolk, VA 23508.
Tel: +1 757-683-2416. Fax: +1-757-451-1010; E-mail: lheller@odu.edu.

One sentence summary: Protein fractionation of donor platelet plasma reveals that the primary inhibitors of *Acinetobacter baumannii* growth are complement and a heat-stable fast form of alpha-2 macroglobulin.

Editor: Patrick Brennan

ABSTRACT

Acinetobacter baumannii is an environmentally resilient healthcare-associated opportunistic pathogen responsible for infections at many body sites. In the last 10 years, clinical strains resistant to many or all commonly used antibiotics have emerged globally. With few antimicrobial agents in the pharmaceutical pipeline, new and alternative agents are essential. Platelets secrete a large number of proteins, including proteins with antimicrobial activity. In a previous study, we demonstrated that donor platelet supernatants and plasma significantly inhibited the growth of a reference strain of *A. baumannii* in broth and on skin. This inhibition appeared to be unrelated to the platelet activation state. In this study, we demonstrate that this growth inhibition extends to clinical multidrug resistant isolates. We also demonstrate that there is no relationship between this activity and selected platelet-derived antimicrobial proteins. Instead, the donor plasma components complement and alpha-2 macroglobulin are implicated.

Keywords: platelets; plasma; growth inhibition; antimicrobial peptides; multidrug resistance; *Acinetobacter baumannii*

Acinetobacter baumannii is primarily found in healthcare settings worldwide (Dijkshoorn, Nemeč and Seifert 2007) and causes pneumonia and bacteremia as well as central nervous system, skin, bone and soft tissue infections (Peleg, Seifert and Paterson 2008). Isolates can be resistant to all commonly used gram-negative antimicrobial agents. With very few treatment options, the development of new antimicrobial agents is imperative (Boucher et al. 2013; Roca et al. 2015).

Platelet gel or platelet-rich plasma is composed of concentrated activated platelets in donor plasma. When activated, platelets secrete a variety of proteins and other molecules, including antimicrobial peptides (AMPs). These AMPs include platelet factor 4 (PF-4)/CXCL-4 (Yeaman et al. 1997), the proteolytic derivatives of platelet basic protein (PBP/CXCL-7/ β -thromboglobulin), thrombocidins 1 and 2 (TC-1 and TC-2) (Krijgsvelde et al. 2000), RANTES/CCL-5 (Tang, Yeaman and Selsted 2002), thymosin β 4 (T β 4) (Tang, Yeaman and Selsted 2002) and

Received: 14 May 2015; Accepted: 15 October 2015

© FEMS 2015. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

IL-8/CXCL-8 (Yount et al. 2007). A previous study established that human donor platelet gel supernatants exhibited antimicrobial properties against *A. baumannii* (Edelblute et al. 2015). Here, we hypothesize that platelet-produced AMPs are responsible for this inhibition and investigate individual platelet gel components.

One-day expired single-donor platelets were purchased from the American Red Cross (Norfolk, VA). Washed platelets were activated with 100 US units mL⁻¹ bovine thrombin or by the application of nanosecond pulsed electric fields (5 pulses, 30 kV/cm 300 ns, 2 Hz, PEFs) as previously described (Edelblute et al. 2015). After clotting, the samples were centrifuged and the supernatants were assayed to avoid direct platelet activation by bacteria (Cox, Kerrigan and Watson 2011). In this study, the separated plasma was referred to as 'donor plasma' to distinguish it from normal human plasma.

Regardless of activation state, platelet supernatants significantly inhibited the growth of several clinical *A. baumannii* isolates. This inhibition of individual isolates was consistent across the donor samples (Fig. 1). Quiescent and PEF-activated, but not thrombin-activated, supernatants significantly inhibited the growth of isolate 2 with respect to the control. Isolates 3, 4 and 8 were sensitive to quiescent and thrombin-activated, but not PEF-activated, supernatants. The growth of isolates 5 and 7 was significantly inactivated by all supernatants. Isolates 1, 6 and 9 were not significantly inhibited by any platelet supernatant. This activity was stable after supernatant exposure to 56°C for 30 minutes.

Interestingly, donor plasma significantly inhibited the growth of eight of the nine clinical isolates, including the six MDR isolates. Therefore, the concentration of the inactivating agent or agents must be highest in the donor plasma. Heat inactivation reduced growth inhibition from 97 to 62% ($P < 0.001$) (data not shown), implicating the activity of complement, an innate, heat labile plasma component with non-specific antibacterial activity. Several groups have demonstrated that serum complement kills *A. baumannii* reference strains, including ATCC 19606, and clinical isolates (Cervi and Monetto 1996; Garcia et al. 2000; Kim et al. 2009; King et al. 2009). The loss of killing after heat exposure implicates activation of the alternative pathway (Cervi and Monetto 1996; Kim et al.

2009; King et al. 2009). However, the residual activity in donor plasma must be attributed to a heat-stable component.

Inhibition of *A. baumannii* by AMPs was first described in 2000 (Giacometti et al. 2000), and platelet-derived AMPs could account for the heat-stable antimicrobial activity. Four of these proteins were quantified in platelet gel supernatants and in donor plasma (Fig. 2). Levels of RANTES, NAP-2/TC-1 and IL-8 were significantly increased by thrombin activation with respect to quiescent platelet gel supernatants. Although PEF application induced platelet aggregation as observed previously (Zhang et al. 2008), no significant increase in AMP levels was detected. Donor plasma contained a significantly reduced concentration of RANTES but a significantly greater concentration of PF-4 than the supernatants, initially implicating PF-4 as an inactivating agent. Platelet-produced PF-4 and its derived peptides are well-studied AMPs (Yeaman et al. 1997; Yeaman 2010) particularly against *Staphylococcus aureus*.

Growth inhibition of *A. baumannii* (ATCC 19606) and control strains *B. subtilis* (ATCC 6633) and *E. coli* (ATCC 25922) by recombinant proteins was assayed at the highest mean concentration detected in any sample type (Fig. 3a). Since increases in concentration for the quantified analytes varied between 2-fold (RANTES), 3-fold (NAP-2/TC-1), 7-fold (IL-8) and 2000-fold (PF-4) over normal serum or plasma levels and Tβ4 was not quantified, this protein was tested at concentration of approximately 10-fold its normal serum concentration (Weller et al. 1988) In initial studies, PF-4 significantly inhibited the growth of *A. baumannii* and *B. subtilis*. However, when additional formulations of PF-4 were tested at the same concentration, including an alternative human PF-4, mouse PF-4 and PF-4 (58-70), a peptide with known antimicrobial activity (Darveau et al. 1992), no growth inhibition was detected (Fig. 3b).

To better identify the heat-stable source of growth inhibition, a supernatant sample was fractionated with size exclusion chromatography. Activity was found in the fractions eluted between 7 and 10 ml of elution volume. These fractions inhibited growth by 30% (Fig. 4) and corresponded to an apparent molecular weight ranging between 400 and 800 kDa. SDS PAGE analysis of the active fractions revealed the presence of multiple proteins, so ion exchange chromatography was applied to the pooled active fractions to reduce this number for identification analysis.




Figure 1. Growth inhibition of clinical *A. baumannii* isolates by platelet supernatants and donor plasma. Multidrug sensitive and resistant clinical *A. baumannii* isolates were cultured from urine, wounds, sputum or the nose of different patients at a local hospital. Identification and antibiotic susceptibilities were determined using a Vitek 2 system (bioMérieux, Durham, NC). Growth of 1000 colony forming units incubated 18 hours with peptides in Mueller Hinton broth (Hancock 2001) was monitored by changes in OD₆₂₀ and compared to control growth. Quiescent, quiescent platelet supernatant; thrombin, thrombin-activated platelet supernatant; PEFs, PEF-activated platelet supernatant; DP, donor plasma. Mean \pm SEM, $n = 5-6$ donors per group. * $P < 0.05$; ** $P < 0.01$ with respect to quiescent supernatants.




Figure 2. Quantification of AMPs in platelet gel supernatants and platelet plasma. Proteins were quantified using a bead-based multiplex assay (EMD Millipore, Billerica, MA, MAGPIX platform, Luminex Corp., Austin, TX). A, RANTES; B, IL-8; C, CXCL7/NAP2; D, PF-4; E, HP. Q, quiescent platelet supernatant; C, supernatant from platelets enriched with CaCl_2 ; T, thrombin-activated platelet supernatant; PEFs, PEF-activated platelet supernatant; DP, donor plasma. Mean \pm SEM, $n = 5-6$ donors per group. * $P < 0.05$; ** $P < 0.01$ with respect to quiescent supernatants.




Figure 3. Growth inhibition by proteins or peptides. A, recombinant AMPs with *A. baumannii* (ATCC 19606), *E. coli* (ATCC 25922) or *B. subtilis* (ATCC 6633); B, recombinant PF-4 formulations with *A. baumannii* (ATCC 19606); C, proteins identified by HPLC ECI-MS/MS with *A. baumannii* (ATCC 19606) or selected clinical isolates. Recombinant IL-8, RANTES and T β 4 (PeproTech, Rocky Hill, NJ), human or mouse PF-4 (PeproTech, Rocky Hill, NJ or R&D Systems, Minneapolis, MN), human PF-4 (58-70) (Bachem, Torrance, CA), purified HP (Sigma Aldrich, St. Louis, NJ) and custom-synthesized TC-1 (NeoBioLab, Woburn, MA) were reconstituted in PBS containing 0.1% BSA. Purified A2M and A2M-FF were buffered by the manufacturer (Athens Research, Athens, GA). ** $P < 0.01$ with respect to controls containing the appropriate buffer.

Activity that inhibited growth by 40% was detected in two peaks eluted in a NaCl gradient. High-performance liquid chromatography/electrospray tandem mass spectrometry (University of Texas Health Science Center, San Antonio, TX) identified two proteins, alpha-2-macroglobulin and haptoglobin (HP).

HP is a natural bacteriostat affecting iron metabolism (Eaton et al. 1982). Since HP levels in donor plasma were more than 10-fold over those of normal plasma (Fig. 2), this concentration was assayed for growth inhibition of the reference strain and three clinical isolates. HP did not inhibit *A. baumannii* growth (Fig. 3c).

A2M is a non-specific protease inhibitor that occurs in a native form and in a proteolytically cleaved, electrophoretically fast form (A2M-FF) (Rehman, Ahsan and Khan 2013). This protein was not quantified; however, it is not found in the platelet proteome (Senzel, Gnatenko and Bahou 2009; Burkhart et al. 2012; van Holten et al. 2014; Zufferey et al. 2014), so the normal plasma concentration of native A2M was assayed for each form. While native A2M did not inhibit growth, two different lots of A2M-FF inhibited the growth of the reference strain by 50%. This activity was heat stable, supporting the concept that this pro-

tein comprised the heat-stable growth-inhibiting component of donor plasma. However, neither form of A2M significantly inhibited the growth of the clinical isolates. While native A2M has a half-life in the circulation of several hours, A2M-FF is immediately endocytosed by hepatocytes and macrophages, resulting in a half-life of 2-4 minutes (Rehman, Ahsan and Khan 2013). Since hepatocytes are not present in donor plasma and macrophages are present in only small numbers, A2M-FF may accumulate in expired platelet plasma and potentially other stored serum or plasma sample types. These proteins may stick to platelets and therefore be present in platelet supernatants.

The potential antimicrobial mechanism of A2M is unknown. The possibility of the direct generation of AMPs was investigated computationally using by HHpred homology modeling (Soding 2005) and structure comparison in 3D-BLAST (Yang and Tung 2006). No apparent AMP motifs (Fjell et al. 2012) were found. Alpha-2 macroglobulin shares about 35-40% homology to complement molecules C3, C4 and C5, which, during activation, generate AMPs known as anaphylatoxins (Pasupuleti et al. 2007). Several conserved domains are shared by A2M and C3, C4 and




Figure 4. Purification of the antimicrobial components of human platelet supernatants. Samples were separated by size exclusion chromatography (Superdex 200, GE Healthcare, Pittsburgh, PA, USA). Antimicrobial activity was assayed through entire elution volume, initially in the pools of five fractions and then in individual fractions. A characteristic elution profile is depicted in blue, antimicrobial activity of corresponding pool fractions is overlaid in red. The inset demonstrates the antimicrobial activity in individual fractions ($n = 3$).

C5. However, the canonical anaphylatoxin (ANATO) domain is not found in the A2M sequence (DELTA-BLAST, National Center for Biotechnology Information, USA). It is worth noting that the region of the putative ANATO domain is not available for structural analysis. This region is disordered in the only available A2M crystal structure (Protein Data Bank ID 4ACQ). Consequently, the possibility of anaphylatoxin-like AMP production is uncertain and requires further investigation.

In this study, we describe growth inhibition of a reference strain and several clinical *A. baumannii* isolates by donor platelet plasma components. As previously published, complement, a heat-labile plasma component, was responsible for a percentage of this inhibition. Unexpectedly, platelet-derived AMPs did not significantly inhibit growth. Sample fractionation, protein identification and activity analysis implicated the fast form of A2M in the growth inhibition of the reference strain only. These results highlight the necessity of screening for potential antimicrobial effects with clinical rather than reference strains. *A. baumannii* in particular is a genetically fluid organism able to acquire virulence and resistance determinants (Gordon and Wareham 2010; Karah et al. 2012); some of these determinants may contribute to the resistance to growth inhibition observed in these isolates. The overall level of inhibition observed in donor plasma was not recapitulated by the individual components, therefore, undiscovered components, acting additively or synergistically, probably contribute to growth inhibition.

ACKNOWLEDGEMENTS

The clinical *A. baumannii* isolates were a kind gift of Tiffany C. Rowland, MT (ASCP).

Conflict of interest. None declared.

REFERENCES

- Boucher HW, Talbot GH, Benjamin Jr DK, et al. 10 x '20 progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. *Clin Infect Dis* 2013;**56**:1685–94.
- Burkhardt JM, Vaudel M, Gambaryan S, et al. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. *Blood* 2012;**120**:e73–82.
- Cervi BM, Monetto AM. Behaviour of *Acinetobacter* strains with normal human serum. *Central Eur J Pub Health* 1996;**4**: 197–200.
- Cox D, Kerrigan SW, Watson SP. Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation. *J Thromb and Haemost* 2011;**9**:1097–107.
- Darveau RP, Blake J, Seachord CL, et al. Peptides related to the carboxyl terminus of human platelet factor IV with antibacterial activity. *J Clin Invest* 1992;**90**:447–55.
- Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant *Acinetobacter baumannii*. *Nat Rev Microbiol* 2007;**5**:939–51.
- Eaton JW, Brandt P, Mahoney JR, et al. Haptoglobin: a natural bacteriostat. *Science* 1982;**215**:691–3.
- Edelblute CM, Donate AL, Hargrave BY, et al. Human platelet gel supernatant inactivates opportunistic wound pathogens on skin. *Platelets* 2015;**26**:13–6.
- Fjell CD, Hiss JA, Hancock RE, et al. Designing antimicrobial peptides: form follows function. *Nat Rev Drug Discov* 2012;**11**: 37–51.
- Garcia A, Solar H, Gonzalez C, et al. Effect of EDTA on the resistance of clinical isolates of *Acinetobacter baumannii* to the bactericidal activity of normal human serum. *J Med Microbiol* 2000;**49**:1047–50.
- Giacometti A, Cirioni O, Del Prete MS, et al. Comparative activities of polycationic peptides and clinically used antimicrobial agents against multidrug-resistant nosocomial isolates of *Acinetobacter baumannii*. *J Antimicrob Chemother* 2000;**46**:807–10.
- Gordon NC, Wareham DW. Multidrug-resistant *Acinetobacter baumannii*: mechanisms of virulence and resistance. *Int J Antimicrob Ag* 2010;**35**:219–26.
- Hancock REW. Minimal inhibitory concentration (MIC), determination for cationic antimicrobial peptides by modified microtitre broth dilution method. Hancock Laboratory Methods. Department of Microbiology and Immunology, University of British Columbia, British Columbia, Canada, 2001. <http://www.cmdr.ubc.ca/bohb/methods.htm> (3 November 2015, date last accessed).
- Karah N, Sundsfjord A, Towner K, et al. Insights into the global molecular epidemiology of carbapenem non-susceptible clones of *Acinetobacter baumannii*. *Drug Resist Update* 2012;**15**:237–47.
- Kim SW, Choi CH, Moon DC, et al. Serum resistance of *Acinetobacter baumannii* through the binding of factor H to outer membrane proteins. *FEMS Microbiol Lett* 2009;**301**: 224–31.
- King LB, Swiatlo E, Swiatlo A, et al. Serum resistance and biofilm formation in clinical isolates of *Acinetobacter baumannii*. *FEMS Immunol Med Mic* 2009;**55**:414–21.
- Krijgsveld J, Zaat SA, Meeldijk J, et al. Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletion products of CXC chemokines. *J Biol Chem* 2000;**275**:20374–81.

- Pasupuleti M, Walse B, Nordahl EA, et al. Preservation of antimicrobial properties of complement peptide C3a, from invertebrates to humans. *J Biol Chem* 2007;**282**:2520–8.
- Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: emergence of a successful pathogen. *Clin Microbiol Rev* 2008;**21**:538–82.
- Rehman AA, Ahsan H, Khan FH. alpha-2-Macroglobulin: a physiological guardian. *J Cell Physiol* 2013;**228**:1665–75.
- Roca I, Akova M, Baquero F, et al. The global threat of antimicrobial resistance: science for intervention. *New Microbes New Infect* 2015;**6**:22–9.
- Senzel L, Gnatenko DV, Bahou WF. The platelet proteome. *Curr Opin Hematol* 2009;**16**:329–33.
- Soding J. Protein homology detection by HMM-HMM comparison. *Bioinformatics* 2005;**21**:951–60.
- Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. *Infect Immun* 2002;**70**:6524–33.
- van Holten TC, Bleijerveld OB, Wijten P, et al. Quantitative proteomics analysis reveals similar release profiles following specific PAR-1 or PAR-4 stimulation of platelets. *Cardiovasc Res* 2014;**103**:140–6.
- Weller FE, Mutchnick MG, Goldstein AL, et al. Enzyme immunoassay measurement of thymosin beta 4 in human serum. *J Biol Response Mod* 1988;**7**:91–6.
- Yang JM, Tung CH. Protein structure database search and evolutionary classification. *Nucleic Acids Res* 2006;**34**:3646–59.
- Yeaman MR. Platelets in defense against bacterial pathogens. *Cell Mol Life Sci* 2010;**67**:525–44.
- Yeaman MR, Tang YQ, Shen AJ, et al. Purification and in vitro activities of rabbit platelet microbicidal proteins. *Infect Immun* 1997;**65**:1023–31.
- Yount NY, Waring AJ, Gank KD, et al. Structural correlates of antimicrobial efficacy in IL-8 and related human kinocidins. *Biochim Biophys Acta* 2007;**1768**:598–608.
- Zhang J, Blackmore PF, Hargrave BY, et al. Nanosecond pulse electric field (nanopulse): a novel non-ligand agonist for platelet activation. *Arch Biochem Biophys* 2008;**471**:240–8.
- Zufferey A, Schwartz D, Noll S, et al. Characterization of the platelet granule proteome: evidence of the presence of MHC1 in alpha-granules. *J Proteomics* 2014;**101**:130–40.